SCHEDULE 13D/A: Major Shareholder Biotechnology Value Fund Reduces Stake in XOMA Royalty Corp Through Private Sale

Biotechnology Value Fund and its affiliates have filed an amended Schedule 13D, disclosing a reduction in their beneficial ownership of XOMA Royalty Corp common stock to 21.6% following a private sale of 392,723 shares at $27.10 per share.

Summary

• Biotechnology Value Fund L.P. (BVF) and its affiliated entities, including BVF II LP and BVF Partners L.P./IL, collectively reported a beneficial ownership of 2,590,303 shares of XOMA Royalty Corp common stock, representing approximately 21.6% of the outstanding shares.
• This ownership percentage is based on 11,966,889 shares outstanding as of May 8, 2025, as reported in XOMA Royalty Corp's Quarterly Report on Form 10-Q filed on May 13, 2025.
• The reporting persons and Partners Managed Accounts collectively hold 5,003 shares of Series X Preferred Stock, which are convertible into an aggregate of 5,003,000 common shares at a 1:1,000 ratio.
• However, the Series X Beneficial Ownership Limitation currently prohibits the conversion of any portion of the Series X Preferred Stock, as it would result in beneficial ownership exceeding 19.99% of the outstanding common shares.
• On May 16, 2025, the Reporting Persons sold a total of 392,723 common shares in a private transaction at a price of $27.10 per share.
• Specifically, BVF sold 127,407 shares and BVF2 sold 265,316 shares in this transaction.
• The aggregate purchase price for the 1,322,758 common shares owned by BVF was approximately $11,151,698, and for the 1,267,545 common shares owned by BVF2 was approximately $12,811,805, both including brokerage commissions.
• The aggregate purchase price for the 5,003 shares of Series X Preferred Stock held by the reporting persons and managed accounts was approximately $20,162,090, including brokerage commissions.

Sentiment

Score: 4

Explanation: The sentiment is slightly cautious. While the document is a factual disclosure, the reduction in stake by a significant institutional investor through a private sale could be interpreted by the market as a less positive signal, even if it's part of routine portfolio management.

Positives

• The reporting persons successfully executed a private sale of a significant block of shares at a specific price of $27.10 per share, indicating liquidity for their holdings.

Negatives

• A major institutional investor reducing its stake could be perceived negatively by the market, potentially signaling a change in investment thesis or portfolio rebalancing.

Risks

• The Series X Beneficial Ownership Limitation prevents the conversion of the 5,003 shares of Series X Preferred Stock into 5,003,000 common shares, limiting the reporting persons' ability to fully realize their potential common stock ownership from these preferred shares.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the issuer's future performance or the reporting persons' future investment intentions beyond the disclosed ownership and recent transaction.

Industry Context

This filing is a routine disclosure of changes in beneficial ownership by a significant institutional investor in a biotechnology royalty company. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The sale of a significant block of shares by a major investor could influence market perception and potentially the share price, depending on the market's interpretation of the investor's motives.
• Management: The company's management may need to address investor inquiries regarding the change in ownership structure and the implications of a large shareholder reducing their stake.

Key Dates

Keywords

XOMA Royalty Corp, Schedule 13D, Beneficial Ownership, Common Stock, Series X Preferred Stock, Institutional Investor, Share Sale, Biotechnology Value Fund, SEC Filing, Investment Management